oa SA Pharmaceutical Journal - Impetigo : a review with a focus on retapamulin : review
|Article Title||Impetigo : a review with a focus on retapamulin : review|
|© Publisher:||Medpharm Publications|
|Journal||SA Pharmaceutical Journal|
|Publication Date||Jan 2015|
|Pages||22 - 25|
|Keyword(s)||Bullous impetigo, Impetigo, Nonbullous impetigo, Retapamulin, Staphylococcus aureus and Steptococcus pyogenes|
Nonbullous impetigo and bullous impetigo, caused by Staphylococcus aureus and Streptococcus pyogenes, can be successfully treated with topical antibiotics. Retapamulin is a semi-synthetic pleuromutilin antibiotic with bacteriostatic properties against S. aureus and S. pyogenes. It prevents bacterial protein synthesis in multiple ways, and therefore reduces the risk of resistance developing. A twice-daily application of retapamulin for five days is effective in treating primary impetigo and secondarily infected traumatic lesions and dermatoses in patients older than nine months of age. The benefits of topical treatment include low systemic absorption, with less side-effects and a lower risk of resistance when compared to oral therapy. Serious adverse events have not been reported with the use of retapamulin. The most commonly reported adverse event has been local skin irritation. If lesions do not improve after 3-4 days of treatment with retapamulin, patients should consult their doctor to further investigate and eliminate the possibility of infection with non-susceptible strains.
Article metrics loading...